Announcement under Regulation 30 (LODR) - Newspaper Publication
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental Limited has submitted to BSE the newspaper clippings (English and Gujarati) of its unaudited Standalone and Consolidated financial results for the quarter and half year ended 30 September 2025, as required under Regulation 30 of the LODR. The results were approved by the Board of Directors on 14 November 2025. On a Standalone basis, Q2 FY26 total income stood at Rs. 1,300.00 lakhs with a net profit after tax of Rs. 59.19 lakhs (EPS of Rs. 0.59), while H1 FY26 total income was Rs. 2,670.86 lakhs and net profit Rs. 114.80 lakhs. On a Consolidated basis, the picture is weaker: Q2 FY26 reported a net loss after tax of Rs. 450.70 lakhs (EPS of -Rs. 1.65) and H1 FY26 a net loss of Rs. 699.50 lakhs (EPS of -Rs. 2.33), despite total income of Rs. 2,094.96 lakhs and Rs. 4,256.75 lakhs respectively. The widening gap between profitable Standalone numbers and loss-making Consolidated numbers points to losses at the subsidiary level weighing on group earnings. Compared with the previous year same period, standalone revenue and profits show a sharp year-on-year decline.
This is a routine regulatory compliance filing (newspaper publication) and does not contain new business news beyond what was already approved on 14 November 2025. For shareholders, the key takeaway is that the company is profitable on a standalone basis but its consolidated entity is in loss, suggesting trouble at the subsidiary level that investors should monitor closely.